342 related articles for article (PubMed ID: 19527097)
1. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
Timur A; Picone G
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
[TBL] [Abstract][Full Text] [Related]
2. Has the European union achieved a single pharmaceutical market?
Timur A; Picone G; DeSimone J
Int J Health Care Finance Econ; 2011 Dec; 11(4):223-44. PubMed ID: 21984119
[TBL] [Abstract][Full Text] [Related]
3. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
Adamini S; Maarse H; Versluis E; Light DW
J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
[TBL] [Abstract][Full Text] [Related]
4. [Parallel import of drug preparations. A study of price development of parallel import preparations versus original preparations].
Schou HS
Ugeskr Laeger; 1993 Jun; 155(26):2024-8. PubMed ID: 8328041
[TBL] [Abstract][Full Text] [Related]
5. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
Martikainen J; Kivi I; Linnosmaa I
Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
[TBL] [Abstract][Full Text] [Related]
6. Comparative approaches to pharmaceutical price regulation in the European Union.
Mrazek MF
Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
[TBL] [Abstract][Full Text] [Related]
7. EU launches measures to stop diversion of cut-price drugs.
Fleck F
Bull World Health Organ; 2003; 81(7):549. PubMed ID: 12973652
[No Abstract] [Full Text] [Related]
8. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
Lichtenberg FR
Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
[TBL] [Abstract][Full Text] [Related]
9. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
[TBL] [Abstract][Full Text] [Related]
10. Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
Felder S
Eur J Health Econ; 2004 Dec; 5(4):324-9. PubMed ID: 15759171
[TBL] [Abstract][Full Text] [Related]
11. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
James JS
AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151
[TBL] [Abstract][Full Text] [Related]
12. The impact of generic substitution on price competition in Finland.
Aalto-Setälä V
Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
[TBL] [Abstract][Full Text] [Related]
13. [The European Union and drugs].
Viala G; Campion MD
Ann Pharm Fr; 1995; 53(4):184-7. PubMed ID: 7574273
[TBL] [Abstract][Full Text] [Related]
14. Prices and availability of biopharmaceuticals: an international comparison.
Danzon PM; Furukawa MF
Health Aff (Millwood); 2006; 25(5):1353-62. PubMed ID: 16966733
[TBL] [Abstract][Full Text] [Related]
15. [Drugs in the European Union: the health-market complex].
Antoñanzas F; Rodríguez R; Sacristán JA; Illa R
Gac Sanit; 2005; 19(2):151-67. PubMed ID: 15860163
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union.
Vogel RJ
Clin Ther; 2004 Aug; 26(8):1327-40; discussion 1326. PubMed ID: 15476914
[TBL] [Abstract][Full Text] [Related]
17. The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.
Danzon PM; Wang YR; Wang L
Health Econ; 2005 Mar; 14(3):269-92. PubMed ID: 15386651
[TBL] [Abstract][Full Text] [Related]
18. EU agrees deal on cheaper drugs for developing world.
Watson R
BMJ; 2003 Jun; 326(7401):1229. PubMed ID: 12791716
[No Abstract] [Full Text] [Related]
19. Pharma Dynamics: targeting safe, effective and affordable medication for South Africa and neighbouring countries.
Cardiovasc J Afr; 2009; 20(1):85. PubMed ID: 19287824
[No Abstract] [Full Text] [Related]
20. Stimulating pharmaceutical innovation in the EU.
Annemans L; Cleemput I; Hulstaert F; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):235-9. PubMed ID: 21671690
[No Abstract] [Full Text] [Related]
[Next] [New Search]
